Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$3.96 - $5.07 $30,123 - $38,567
-7,607 Reduced 42.75%
10,188 $43,000
Q2 2024

Jul 29, 2024

BUY
$3.66 - $5.34 $25,521 - $37,235
6,973 Added 64.43%
17,795 $71,000
Q1 2024

Apr 29, 2024

SELL
$4.19 - $5.59 $3,050 - $4,069
-728 Reduced 6.3%
10,822 $53,000
Q4 2023

Feb 07, 2024

SELL
$3.18 - $4.9 $3,657 - $5,635
-1,150 Reduced 9.06%
11,550 $54,000
Q3 2023

Nov 02, 2023

BUY
$2.97 - $3.88 $37,719 - $49,276
12,700 New
12,700 $48,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.